| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
| US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
| US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
| US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
| US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(3 months from now) | |
| US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(7 years from now) | |
| US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(8 years from now) | |
| US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(8 years from now) | |
| US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) | |
Linzess is owned by Allergan.
Linzess contains Linaclotide.
Linzess has a total of 12 drug patents out of which 0 drug patents have expired.
Linzess was authorised for market use on 30 August, 2012.
Linzess is available in capsule;oral dosage forms.
Linzess can be used as method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients., method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients., method of treating chronic idiopathic constipation in adult patients., method of treating irritable bowel syndrome with constipation in adults; method of treating chronic idiopathic constipation in adult patients..
The generics of Linzess are possible to be released after 16 August, 2033.
Drugs and Companies using LINACLOTIDE ingredient
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constip...
Dosage: CAPSULE;ORAL
LINZESS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic